M Svenson
Overview
Explore the profile of M Svenson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
1272
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steenholdt C, Svenson M, Bendtzen K, Thomsen O, Brynskov J, Ainsworth M
Aliment Pharmacol Ther
. 2011 May;
34(1):51-8.
PMID: 21535447
Background: Infliximab (IFX) elicits acute severe infusion reactions in about 5% of patients with inflammatory bowel disease (IBD). Aim: To investigate the role of anti-IFX antibodies (Ab) and other risk...
2.
Radstake T, Svenson M, Eijsbouts A, Van den Hoogen F, Enevold C, Van Riel P, et al.
Ann Rheum Dis
. 2008 Nov;
68(11):1739-45.
PMID: 19019895
Background: Tumour necrosis factor alpha (TNFalpha) neutralising antibody constructs are increasingly being used to treat rheumatoid arthritis (RA). Objective: To determine potential differences in clinical responses, soluble drug levels and...
3.
Svenson M, Geborek P, Saxne T, Bendtzen K
Rheumatology (Oxford)
. 2007 Nov;
46(12):1828-34.
PMID: 18032541
Objectives: Infliximab is an anti-tumour necrosis factor-alpha (TNF-alpha) mouse-human IgG1/kappa antibody used to treat patients with rheumatoid arthritis (RA) and other inflammatory diseases. Unfortunately, response failure and side-effects due to...
4.
Hansen M, Galle P, Salomo M, Svenson M, Dickmeiss E, Gimsing P
Vox Sang
. 2007 Mar;
92(3):213-23.
PMID: 17348870
Background: For some unknown reason humans may 'spontaneously' produce high amounts of neutralizing autoantibodies to a number of growth factors and cytokines. Reaching a certain high level the antibodies render...
5.
Ejrnaes A, Svenson M, Lund G, Larsen J, Jacobi H
Clin Exp Allergy
. 2006 Feb;
36(3):273-82.
PMID: 16499637
Background: Human basophils and mast cells express the low-affinity immunoglobulin (Ig)G receptor FcgammaRIIB. It has previously been shown in artificial model systems that cross-linking of the high-affinity IgE receptor FcepsilonRI...
6.
Bodtger U, Ejrnaes A, Hummelshoj L, Jacobi H, Poulsen L, Svenson M
Int Arch Allergy Immunol
. 2005 Mar;
136(4):340-6.
PMID: 15741732
Background: The role of IgG4 during allergen-specific immunotherapy (SIT) is still controversial. The available studies present paramount differences in in vitro techniques, allergens, and clinical outcome parameters. By implementing a...
7.
Gudbrandsdottir S, Larsen R, Sorensen L, Nielsen S, Hansen M, Svenson M, et al.
Clin Exp Rheumatol
. 2004 Mar;
22(1):118-24.
PMID: 15005015
Background: Etanercept (Enbrel) induces a rapid and sustained decline in disease activity in the majority of patients with refractory juvenile idiopathic arthritis (JIA). For unknown reasons, however, a number of...
8.
Graudal N, Svenson M, Tarp U, Garred P, Jurik A, Bendtzen K
Ann Rheum Dis
. 2002 Jun;
61(7):598-602.
PMID: 12079899
Objectives: To investigate the possible association of interleukin 1alpha autoantibodies (IL1alpha aAb) with the long term course of joint erosion in patients with rheumatoid arthritis (RA). Methods: Serum samples from...
9.
Bendtzen K, Bovin L, Andersen V, Rieneck K, Svenson M
Ugeskr Laeger
. 2001 Sep;
163(34):4562-5.
PMID: 11530561
No abstract available.
10.
Forslind K, Svensson B, Svenson M, Bendtzen K
Scand J Rheumatol
. 2001 Jul;
30(3):167-8.
PMID: 11469528
Objective: To investigate the potential predictive value of autoantibodies against IL1-alpha (anti-IL-1alpha) in patients with early rheumatoid arthritis (RA). Method: Anti-IL-1alpha were assessed by radioimmunoassay in sera from 164 patients...